Dashboard
Manage Tickers

INZY Inozyme Pharma, Inc.

Nasdaq inozyme.com


$ 3.99 $ 0.01 (0.25 %)    

Monday, 30-Jun-2025 18:10:36 EDT
CLICK TO SEE RELEVANT LITIGATION UPDATES
Y-mAbs Therapeutics, Inc. | YMAB | Take Action!
QQQ $ 612.11 $ 7.61 (1.26 %)
DIA $ 467.12 $ 5.24 (1.13 %)
SPY $ 671.75 $ 6.91 (1.04 %)
TLT $ 91.68 $ 0.35 (0.38 %)
GLD $ 401.36 $ 14.16 (3.64 %)
$ 4
$ 4.00
$ 0.00 x 0
$ 0.00 x 0
-- - --
$ 0.72 - $ 6.24
1,459,443
na
258.25M
$ 2.09
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 05-14-2025 03-31-2025 10-Q
2 03-10-2025 12-31-2024 10-K
3 11-05-2024 09-30-2024 10-Q
4 08-06-2024 06-30-2024 10-Q
5 05-07-2024 03-31-2024 10-Q
6 03-12-2024 12-31-2023 10-K
7 11-07-2023 09-30-2023 10-Q
8 08-08-2023 06-30-2023 10-Q
9 05-09-2023 03-31-2023 10-Q
10 03-22-2023 12-31-2022 10-K
11 11-10-2022 09-30-2022 10-Q
12 08-15-2022 06-30-2022 10-Q
13 05-10-2022 03-31-2022 10-Q
14 03-15-2022 12-31-2021 10-K
15 11-09-2021 09-30-2021 10-Q
16 08-11-2021 06-30-2021 10-Q
17 05-12-2021 03-31-2021 10-Q
18 03-25-2021 12-31-2020 10-K
19 11-12-2020 09-30-2020 10-Q
20 09-03-2020 06-30-2020 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

wells-fargo-downgrades-inozyme-pharma-to-equal-weight-announces-4-price-target
Wells Fargo Downgrades Inozyme Pharma to E...
05/16/2025 22:29:42

Wells Fargo analyst Tiago Fauth downgrades Inozyme Pharma (NASDAQ:INZY) from Overweight to Equal-Weight and announces $4 pri...

jefferies-downgrades-inozyme-pharma-to-hold-lowers-price-target-to-4
Jefferies Downgrades Inozyme Pharma to Hol...
05/16/2025 20:10:08

Jefferies analyst Ryan Deschner downgrades Inozyme Pharma (NASDAQ:INZY) from Buy to Hold and lowers the price target from $1...

gold-down-over-1-flowers-foods-posts-weak-earnings
Gold Down Over 1%; Flowers Foods Posts Wea...
05/16/2025 17:37:00

Core News & Articles
12 Health Care Stocks Moving In Friday's I...
05/16/2025 17:06:37

needham-downgrades-inozyme-pharma-to-hold-maintains-price-target-to-12
Needham Downgrades Inozyme Pharma to Hold,...
05/16/2025 16:57:34

Needham analyst Joseph Stringer downgrades Inozyme Pharma (NASDAQ:INZY) from Buy to Hold and maintains the price target from...

us-stocks-edge-higher-consumer-sentiment-falls-in-may
US Stocks Edge Higher; Consumer Sentiment ...
05/16/2025 14:22:46

Core News & Articles
12 Health Care Stocks Moving In Friday's P...
05/16/2025 12:08:31

trading-halt-halt-status-updated-at-75500-am-et-quotation-resumption-news-and-resumption-times
Trading Halt: Halt status updated at 7:55:...
05/16/2025 11:55:09

Core News & Articles
BioMarin Agrees To Acquire Inozyme For $4....
05/16/2025 11:33:33

Acquisition is Strong Strategic Fit for BioMarin, Adding INZ-701, a Phase 3 Enzyme Replacement Therapy Being Developed for Trea...

trading-halt-halted-at-72500-am-et---trading-halt-halt-news-pending
Trading Halt: Halted at 7:25:00 a.m. ET - ...
05/16/2025 11:25:04

needham-maintains-buy-on-inozyme-pharma-lowers-price-target-to-12
Needham Maintains Buy on Inozyme Pharma, L...
05/14/2025 18:15:22

Needham analyst Joseph Stringer maintains Inozyme Pharma (NASDAQ:INZY) with a Buy and lowers the price target from $15 to $12.

inozyme-pharma-q1-eps-044-misses-041-estimate
Inozyme Pharma Q1 EPS $(0.44) Misses $(0.4...
05/14/2025 11:35:14

Inozyme Pharma (NASDAQ:INZY) reported quarterly losses of $(0.44) per share which missed the analyst consensus estimate of $(0....

hc-wainwright--co-reiterates-buy-on-inozyme-pharma-maintains-16-price-target
HC Wainwright & Co. Reiterates Buy on Inoz...
04/10/2025 15:07:26

HC Wainwright & Co. analyst Edward White reiterates Inozyme Pharma (NASDAQ:INZY) with a Buy and maintains $16 price target.

inozyme-pharma-publishes-paper-titled--phenotypic-characterization-of-enpp1-deficiency-generalized-arterial-calcification-of-infancy-and-autosomal-recessive-hypophosphatemic-rickets-type-2-in-jbmr-plus
Inozyme Pharma Publishes Paper Titled "Ph...
04/10/2025 12:36:26

- Data from the largest retrospective analysis of ENPP1 Deficiency provides insights into the evolution of the disease's se...

needham-reiterates-buy-on-inozyme-pharma-maintains-15-price-target
Needham Reiterates Buy on Inozyme Pharma, ...
04/08/2025 12:31:20

Needham analyst Joseph Stringer reiterates Inozyme Pharma (NASDAQ:INZY) with a Buy and maintains $15 price target.

raymond-james-maintains-outperform-on-inozyme-pharma-lowers-price-target-to-12
Raymond James Maintains Outperform on Inoz...
03/12/2025 16:40:52

Raymond James analyst Ryan Deschner maintains Inozyme Pharma (NASDAQ:INZY) with a Outperform and lowers the price target fro...

piper-sandler-maintains-overweight-on-inozyme-pharma-lowers-price-target-to-23
Piper Sandler Maintains Overweight on Inoz...
03/11/2025 16:05:45

Piper Sandler analyst Allison Bratzel maintains Inozyme Pharma (NASDAQ:INZY) with a Overweight and lowers the price target f...

needham-maintains-buy-on-inozyme-pharma-lowers-price-target-to-15
Needham Maintains Buy on Inozyme Pharma, L...
03/11/2025 11:08:30

Needham analyst Joseph Stringer maintains Inozyme Pharma (NASDAQ:INZY) with a Buy and lowers the price target from $23 to $15.

hc-wainwright--co-reiterates-buy-on-inozyme-pharma-maintains-16-price-target
HC Wainwright & Co. Reiterates Buy on Inoz...
03/11/2025 10:41:20

HC Wainwright & Co. analyst Edward White reiterates Inozyme Pharma (NASDAQ:INZY) with a Buy and maintains $16 price target.

inozyme-pharma-fy-2024-gaap-eps-162-misses-160-estimate-co-prioritizes-activities-to-support-planned-biologics-license-application-filing-for-inz-701-in-enpp1-deficiency-announces-25-workforce-reduction
Inozyme Pharma FY 2024 GAAP EPS $(1.62) Mi...
03/10/2025 12:36:09

CORE & Plaid

CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION